FOCUSED REVIEW Treatment for Pulmonary Arterial Hypertension–Associated Right Ventricular Dysfunction Jose Gomez-Arroyo1,2, Julio Sandoval2, Marc A. Simon3, Erick Dominguez-Cano2, Norbert F. Voelkel4, and Harm J. Bogaard5 1
Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania; 2Departamento de Cardioneumologia, Instituto Nacional de Cardiologia “Ignacio Chavez,” Mexico City, Mexico; 3Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 4Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia; and 5Department of Pulmonary Medicine, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
Abstract Pulmonary arterial hypertension (PAH) includes a heterogeneous group of diseases characterized by pulmonary vasoconstriction and remodeling of the lung circulation. Although PAH is a disease of the lungs, patients with PAH frequently die of right heart failure. Indeed, survival of patients with PAH depends on the adaptive response of the right ventricle (RV) to the changes in the lung circulation. PAH-speciﬁc drugs affect the function of the RV through afterload reduction and perhaps also through direct effects on the myocardium. Prostacyclins, type 5 phosphodiesterase inhibitors, and guanylyl cyclase stimulators may directly enhance myocardial contractility through increased cyclic adenosine and guanosine monophosphate availability. Although this may initially improve cardiac performance, the long-term effects on myocardial oxygen consumption and function are unclear. Cardiac effects of endothelin receptor antagonists may be opposite, as
endothelin-1 is known to suppress cardiac contractility. Because PAH is increasingly considered as a disease with quasimalignant growth of cells in the pulmonary vascular wall, therapies are being developed that inhibit hypertrophy and angiogenesis, and promote apoptosis. The inherent danger of these therapies is a further compromise to the already ischemic, ﬁbrotic, and dysfunctional RV. More recently, the right heart has been identiﬁed as a direct treatment target in PAH. The effects of well established therapies for left heart failure, such as b-adrenergic receptor blockers, inhibitors of the renin–angiotensin system, exercise training, and assist devices, are currently being investigated in PAH. Future treatment of patients with PAH will likely consist of a multifaceted approaches aiming to reduce the pressure in the lung circulation and improving right heart adaptation simultaneously. Keywords: heart failure; pharmacology; pulmonary heart disease; right ventricle
(Received in original form December 4, 2013; accepted in final form June 10, 2014 ) Correspondence and requests for reprints should be addressed to Harm Jan Bogaard, M.D., Ph.D., Department of Pulmonary Medicine, VU University Medical Center, PO Box 7057, Amsterdam 1007 MB, The Netherlands. E-mail: [email protected]
Ann Am Thorac Soc Vol 11, No 7, pp 1101–1115, Sep 2014 Copyright © 2014 by the American Thoracic Society DOI: 10.1513/AnnalsATS.201312-425FR Internet address: www.atsjournals.org
The primary determinant of survival in pulmonary arterial hypertension (PAH) is the response of the right ventricle (RV) to the functional and structural alterations of the pulmonary circulation (1–3). As reviewed recently (4), PAH-associated RV failure is thought to result from multiple interactions between an increased afterload and a derailed autocrine, paracrine, and neuroendocrine signaling, ultimately leading to RV–arterial uncoupling, a loss of cardiomyocytes, metabolic remodeling, mitochondrial dysfunction, maladaptive Focused Review
changes of the extracellular matrix, myocardial ischemia, and inﬂammation (5). The relative importance of these interacting pathological mechanisms is unclear, and the impact of current PAH treatments on the adapting RV are, likewise, obscure. In this Review, we sought to recapitulate some of the known effects of standard PAH treatments on the heart, as well as to explore potentially new additional therapies to directly treat RV failure. The pharmacological management of acute RV failure (with inotropes or vasopressors) is
not a topic included in this Review, and we refer the interested reader to existing reviews on this matter (6).
Current PAH-speciﬁc Pharmacotherapies and Their Effect on the RV Guidelines for the treatment of patients with PAH recommend oxygen and diuretics as needed, as well as anticoagulants in patients without contraindications (7, 8). Calcium 1101
FOCUSED REVIEW Table 1. Proposed direct cardiac effects of current pulmonary arterial hypertension therapies and their impact on the right ventricle Treatment
Prostacyclin analogs Endothelin receptor blockers PDE-5 inhibitors/sGC inducers Tyrosine kinase inhibitors Rho-kinase inhibitors
Proposed Direct Cardiac Effects
Impact on the Right Ventricle
↑Angiogenesis ↓Fibrosis Negative inotrope ↑Cardiomyocyte apoptosis ↓Cardiomyocyte apoptosis ↑Myocardial relaxation ↑Contractility ↓Angiogenesis ↑Mitochondrial Dysfunction ↑Cardiomyocyte apoptosis ↓Noncardiomyocyte apoptosis ↓Inﬂammation ↓Contractility Excessive reduction of hypertrophy ↓ROS production ↑Nitric oxide production ↓Inﬂammation
Positive effect Negative effect Positive effect Negative effect Positive effect Negative effect Positive effect
Definition of abbreviations: PDE-5 = phosphodiesterase-5; ROS = reactive oxygen species; sCG = soluble guanylate cyclase.
channel blockers are used in patients with signiﬁcant pulmonary vascular reactivity, whereas other symptomatic patients are
treated with prostacyclin (PGI2) analogs, endothelin (ET)-1 receptor antagonists, and type 5 phosphodiesterase (PDE5)
inhibitors, alone or in combinations (7). It is clear that current pharmacotherapies improve pulmonary hemodynamics, cardiac performance, and functional class of patients with PAH; however, whether any of the clinical beneﬁts from the above-mentioned groups of drugs can be explained by direct effects on the RV has not yet been fully investigated. When it comes to the evaluation of direct RV effects of vasodilator treatment in PAH, two pathophysiological concepts need to be considered. First, RV contractility is greater than normal in virtually all patients with PAH, and, therefore, RV dysfunction is best explained by an increase in afterload out of proportion to the increase in RV contractility (RV–arterial uncoupling, assessed using pressure–volume analysis) (9). RV–arterial coupling can be improved by either an increase in contractility or by a decrease in afterload. Even if a pulmonary vasodilator drug has negative inotropic effects, it could still improve RV–arterial coupling, as long as the decrease in afterload is larger than the decrease in contractility. Second, although a short-term increase in contractility may be beneﬁcial, long-term effects of enhanced contractility
Table 2. Potential RV-targeted therapies and the direct or indirect effects on the right ventricle Drug
Proposed Effects on RV Function
Evidence for Use in PAH
↑Angiogenesis ↓Heart rate ↓Fibrosis Metabolic modulator
Only experimental evidence in animal models
↓Maladaptive hypertrophy ↓RV Volume-overload (by diuresis) ↓Apoptosis ↓Fibrosis Metabolic modulator Systemic vasodilators ↓Remodeling of extracellular matrix ↓Fibrosis ↑Fibrosis ↓Angiogenesis ↑Cardiomyocyte apoptosis
Blockers of the renin–angiotensin–aldosterone Axis HDAC inhibitors (trichostatin-A and valproic acid)
Antioxidants (BH4, protandim)
↓Fibrosis ↓Apoptosis ↓ROS-induced damage
No evidence Only experimental evidence in animal models Only experimental evidence in animal models One clinical trial: improved exercise capacity and increase 6-min walk distance
Definition of abbreviations: BH4 = tetrahydrobiopterin; HDAC = histone deacytelase; PAH = pulmonary arterial hypertension; ROS = reactive oxygen species; RV = right ventricle.
AnnalsATS Volume 11 Number 7 | September 2014
FOCUSED REVIEW (and an accompanying increase in myocardial oxygen consumption) may be detrimental. In other words, increasing contractility might not be the ideal longterm goal of treatment if cardiac cellular homeostasis has not been similarly restored. Supportive Treatment and Calcium Channel Blockers
Oxygen is thought to lower pulmonary vascular resistance by releasing hypoxic pulmonary vasoconstriction and decelerating vascular remodeling; a target oxygen saturation of 90% has been recommended (10). There is no evidence for direct effects of supplemental oxygen on the RV in PAH, although either a protection against ischemia (11) or an increased production of reactive oxygen species (ROS) and suppression of hypoxiainducible factor-1a expression could be hypothesized. The consensus use of anticoagulant therapy is based on indirect evidence (12, 13); however, a recent analysis from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension reported that—at least in patients with idiopathic PAH— anticoagulant therapy was associated with a signiﬁcantly better 3-year survival when compared with patients who never received anticoagulation (13). Although there are data to suggest that digoxin treatment results in an acute increase in cardiac output along with a reduction in serum norepinephrine levels (14), the long-term beneﬁt of digoxin in PAH remains unclear. Diuretic treatment leads to symptomatic improvement in the ﬂuid-overloaded patient. The beneﬁcial effect of the aldosterone antagonist, spironolactone, in heart failure, however, is also associated with immune modulation, reversal of maladaptive remodeling, and prevention of hypokalemia and arrhythmia, which are all potentially important, but unexplored, mechanisms in RV dysfunction associated with PAH (15). Calcium channel blockers are used by a small group of patients with PAH with a positive vasoreactivity test in whom a survival beneﬁt has been suggested (12). The consequences of potentially negative inotropic effects of calcium channel blockers on RV function in PAH are unknown, although dihydropyridine-type calcium channel blocker (nifedipine and Focused Review
amlodipine) are generally considered safe in PAH. Prostacyclin Analogs
For almost 20 years, intravenous administration of epoprostenol (synthetic PGI2) has been the cornerstone of PAH treatment (16). It is generally assumed that the therapeutic effect of PGI2 in PAH is explained by an induction of pulmonary vasodilatation and inhibition of vascular remodeling (17). However, no evidence exists that chronic prostacyclin treatment reverses lung vessel remodeling in PAH (18), and there are histological data to suggest that pulmonary vascular remodeling in PAH progresses despite long-term PGI2 treatment (19). Pogoriler and colleagues (20) reported that long-term prostacyclin treatment might have an antithrombotic effect, but does not prevent or reverse the formation of advanced vascular lesions. It has to be recognized, however, that PGI2 has important direct effects on the heart. In patients with severe heart failure, PGI2 treatment results in an immediate and substantial increase in cardiac output and a reduction in cardiac ﬁlling pressures (21). Recent work shows that, unlike other pulmonary vasodilators, PGI2 analogs improve RV stroke work in PAH (22), which is probably a better reﬂection of cardiac function than cardiac output. Although this improvement in cardiac function could be an adaptive response to systemic vasodilation or the result of pulmonary vasodilation with improved right ventriculo–arterial coupling (21,23), a direct effect on cardiac cells and cell signaling pathways is another possibility. In an animal model of ﬂow-associated PAH, a PGI2 analog, iloprost, improved RV contractility and capillary-to-myocyte ratio, independently from a change in RV afterload (24). Syed and colleagues (25) recently reported that treatment with iloprost does not modify the pulmonary artery pressure (PAP), but does improve RV contractility and reduces ﬁbrosis in the sugen (SU5416)/hypoxia rat model of RV failure and severe PAH. In addition, PGI2 has been reported to suppress pressure overload–induced left ventricular (LV) hypertrophy (26) and ﬁbrosis (27). Both effects are considered to originate from the action of cells other than cardiomyocytes; however, the exact mechanism remains undetermined (26).
Potentially beneﬁcial direct effects of PGI2 treatment on the heart were the main reason for initiating large clinical trials with epoprostenol treatment in patients with severe left heart failure. Unexpectedly, and despite previous positive results, 6 months of treatment with epoprostenol were associated with increased mortality (28, 29). A possible explanation for this adverse outcome was the increase in cardiac output upon initiation of epoprostenol therapy (21). As such, increases in myocardial contractility and cardiac output may initially improve exercise capacity, but the accompanying increase in myocardial oxygen consumption could be detrimental in the long term. Such a sequence of events could be related to the results from the Beraprost Study, which is the only randomized clinical trial with a follow-up time of 1 year with speciﬁc PAH therapy. It was reported that, although exercise capacity improved after 12 weeks of treatment with an oral PGI2 analog, this beneﬁt disappeared after 1 year (30). Indeed, the effects of prostacyclin analogs on the function of the RV are still poorly understood. An increase in myocardial contractility may play a different role in PAH (where improved RV–arterial coupling is desired) when compared with end-stage left heart disease. In the future, it will be important to evaluate whether any potential direct cardiac effects of prostacyclin treatment depend on exposure time or are just an idiosyncratic response to therapy, speciﬁc for every patient. ET Receptor Blockers
In PAH and heart failure, ET-1 serum concentrations are elevated due to increased production by endothelial cells and cardiomyocytes in response to various stimuli (e.g., vasoactive hormones, growth factors, shear stress, hypoxia, and ROS) (31–34). ET-1 not only increases pulmonary vascular tone, but also regulates a variety of biological processes in nonvascular tissues. ET-1 augments cardiomyocyte contractility and plays a role in the development of pressure overload–induced cardiac hypertrophy (31, 35). In patients with PAH–associated heart failure, the direct effects of ET-1 signaling on the heart are mixed with indirect effects via stimulation of pulmonary vasoconstriction and vascular remodeling. ET-1 exerts its effects through two receptor subtypes, ETA and ETB, the former predominating in the rat 1103
FOCUSED REVIEW myocardium (36). Heart failure in rats leads to an increased ETA receptor density (33). ET-1 affects cardiomyocyte survival and pressure overload–induced hypertrophy by interacting with B-cell lymphoma 2 (37), the epidermal growth factor (EGF) receptor (EGF-R) (38), and mitogen-activated protein kinase (PK) cascades (35). Clinical trials in patients with left-sided heart failure with orally administered ET receptor antagonists (Research on Endothelin Antagonism in Chronic Heart Failure-1, Enrasentan Cooperative Randomized Evaluation, Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure, and Endothelin A Receptor Antagonist Trial in Heart Failure were the largest, although the results have never been fully published) suggest that direct effects of ET receptor antagonists on the heart are not favorable (39–41). It has been postulated that the inotropic actions of ET-1 are, in fact, beneﬁcial in chronic heart failure, providing partial compensation for a decreased contractility. Detrimental actions of ET receptor blocker in the RV of patients with PAH have not (yet) been shown. Experimental studies, however, do suggest that ET receptor blockade worsens the contractility of the pressureoverloaded RV in rats (42). Whether this occurs in PAH and would translate into negative effects for individual patients would depend on the relative magnitudes of decreases in afterload and contractility and the resultant effect on RV–arterial coupling. PDE Inhibitors
Cyclic guanosine monophosphate (cGMP) is a ubiquitous intracellular secondary messenger. The natriuretic peptides generate cGMP via activation of the particulate guanyl cyclase, whereas nitric oxide (NO) induces the formation of cGMP through activation of soluble guanylate cyclase (sGC) (43). cGMP is degraded by the action of PDEs. Some PDE subtypes hydrolyze only cGMP (PDE5, PDE6, and PDE9), whereas others degrade cAMP (PDE3, PDE4, PDE7, and PDE8) or both cGMP and cAMP (PDE1 and PDE2) (44). cGMP lowers Ca21 sensitivity and intracellular Ca21 concentration in pulmonary vascular smooth muscle cells. The resulting vasodilating and antiproliferative properties of the molecule explain the therapeutic beneﬁt of the PDE5 inhibitors, sildenaﬁl and tadalaﬁl, in PAH (45;46). More recently, the therapeutic beneﬁt of increasing cGMP availability with the sGC stimulator, 1104
Riociguat, has been shown in a randomized clinical trial (47). cGMP/PKG signaling protects the heart from apoptosis (48, 49) and blunts the hypertrophic response to pressure overload and isoproterenol (an adrenergic agonist) (50–52). Multiple roles for cGMP in cardiac contractility, lusitropy, and ion channel responsivity have been well characterized; however, the extent to which natriuretic peptides predominate over NO to mediate these effects is less clear (53). The effect of cGMP on myocardial contractility depends on its interactions with PDEs and cAMP. Theoretically, cGMP can decrease contractility by decreasing cAMP concentrations through inhibition of adenylate cyclase and induction of PDE2 (54, 55). In addition, phosphorylation of troponin I by a cGMP-dependent PK can decrease the sensitivity of the contractile apparatus to Ca21 and accelerate myocardial relaxation (54). On the other hand, it was recently shown in patients with PAH and in rats with monocrotaline (MCT)-induced RV hypertrophy, that cGMP can, in fact, increase contractility by increasing cAMP concentrations (56). The authors explained this apparent paradox by cGMP-related inhibition of the cGMP-sensitive PDE3. They also showed that, compared with a normal RV, RV hypertrophy (both in humans and rats) is associated with a considerable decrease in PKG activity. At the same time, PDE5 was only expressed in the hypertrophic RV, and not in the normal RV (56). Once again, the long-term effects of PDE5 inhibition and sGC stimulation on RV adaptation in PAH are unknown. The initial preclinical evidence seemed to justify a provisional conclusion that these strategies could have positive direct effects on the heart. PDE5 inhibition prevents and reverses pressure overload–induced hypertrophy in mice, which was associated with enhanced systolic function (52). Sildenaﬁl protects against cardiomyocyte apoptosis (48, 49), and may decrease myocardial oxygen consumption by inhibiting adenylate cyclase (55) and accelerating myocardial relaxation (54). Despite such positive experimental data, clinical studies of drugs that increase cGMP availability in patients with heart failure have yielded mixed results. After ﬁrst positive results of PDE5 inhibition in patients with non-PAH heart failure with decreased (57, 58) and preserved ejection
fraction (59), recent randomized clinical trials using sildenaﬁl and riociguat in these patient categories failed to meet their primary endpoints (60, 61). A single dose of sildenaﬁl was shown to improve RV diastolic function in patients with PAH (62). It remains to be determined whether this is a direct cardiac effect, or whether it was mediated by a decrease in RV afterload.
New Treatment Strategies in PAH: Good for the Lung, Bad for the Heart? One hypothesis that has been advanced to explain the pathobiology of severe PAH is based on the concept of a quasimalignant nature of endothelial cells in the lung vasculature. This hypothesis postulates that, after an initial injury, pulmonary vascular endothelial cells undergo apoptosis, but a group of surviving cells switch their phenotype and become apoptosis resistant and hyperproliferative to the point of lumen occlusion. In other words, the hypothesis reﬂects a process of “wound healing gone awry” (5). There is now a search for molecular targets and mechanisms that could potentially drive this “quasimalignant” lung vessel remodeling. However, as the knowledge of the pathobiology of PAH evolves, future therapeutic strategies face one critical paradox: although the remodeled lung vasculature in PAH is characterized by angiogenesis, apoptosis resistance, and cell proliferation, the failing RV may suffer from ischemia, capillary rarefaction, and cardiomyocyte apoptosis (63). Thus, new treatments designed to tackle any quasimalignant feature in the sick-lung circulation could have detrimental effects in an ischemic, ﬁbrotic, and dysfunctional RV. Experimental Models of RV Dysfunction
As is the case with many other diseases, potential new compounds for the treatment of PAH are generally tested ﬁrst in animals. Several experimental models have been developed, and the interested reader is referred to a recent review on this topic providing a detailed overview (64). Rat models have generally provided superior insights into the mechanisms of severe pulmonary vascular disease and associated RV failure, as severe pulmonary hypertension is very difﬁcult to induce
AnnalsATS Volume 11 Number 7 | September 2014
FOCUSED REVIEW in mice (65). Pulmonary artery banding, which creates mechanical stress on the RV without pulmonary vascular disease, has been useful to explore side effects of drugs on RV adaptation without the interfering effects from changes in pulmonary vascular resistance (63, 66). Tyrosine Kinase Inhibitors
Platelet-derived growth factor (PDGF) has been implicated in the pathobiology of pulmonary vascular remodeling in PAH (67), and treatment with imatinib, an inhibitor of the tyrosine kinase domain of the PDGF receptor, has been beneﬁcial in isolated cases (68–71). Nonetheless, a phase II trial with patients with PAH failed to meet its primary endpoint of improved exercise capacity after 4 months (72), and a randomized clinical trial in selected patients with PAH (pulmonary vascular resistance > 800 dyne$s$cm 25 ; Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efﬁcacy Study [IMPRES]) showed no improvements in functional class, time to clinical worsening, or mortality with imatinib, despite a small improvement in exercise capacity (73). The trial was discontinued because of severe side effects, in particular subdural hematoma. Another major concern with imatinib treatment in PAH is the fact that the drug may have detrimental effects on the heart (74, 75). After myocardial infarction, PDGF enhances cardiomyocyte survival, modulates inﬂammatory responses, and activates proangiogenic progenitor cells (76–78). Because RV capillary rarefaction and ischemia may play a role in the transition from adaptive hypertrophy to RV dilatation and failure (4, 63), imatinib could potentially worsen maladaptive cardiac remodeling in PAH. Negative direct cardiac effects were not seen in a post hoc analysis of echocardiographic parameters in patients treated with imatinib in the IMPRES trial, however (79). In contrast to PDGF receptor blockers, EGF-R blockers may have beneﬁcial effects on both pulmonary vascular and RV remodeling. In maladaptive cardiac remodeling, activation of the type 1 angiotensin (AT) receptor (AT1R), the mineralocorticoid receptor, and the type A ET receptor (ETA) results in a transactivation of the EGF-R (38, 80, 81). Moreover, pulmonary hypertension in rats with MCT-induced PAH is ameliorated Focused Review
by EGF-R blockers (82). Interestingly, although not mechanistically tested, the reduced RV hypertrophy observed in this study might not have been necessarily the result of a reduced afterload, but could have resulted from decreased myocardial ﬁbrosis and inﬂammation. Paradoxically, tyrosine kinase inhibitors are not only potential treatments for PAH, they have also been implicated in the development of the disease. First, the vascular endothelial growth factor receptor tyrosine kinase inhibitor, SU5416, in combination with a hypoxic or allergic challenge, has provided a useful tool to study PAH in rats (83). Second, Dasatinib, a dual c-src tyrosine kinase/Abelson kinase inhibitor used in the treatment of chronic myelogenous leukemia, was associated with cases of severe PAH, potentially reversible after dasatinib withdrawal (84). Possible dual effects of tyrosine kinase inhibitors need to be taken into account if this group of drugs is to be further developed for PAH treatment. Rho Kinase Inhibitors and 3-Hydroxy3-Methyl-Glutaryl-CoA Reductase Inhibitors (Statins)
Inhibition of Rho kinase (ROCK) has been suggested as a new target for PAH treatment. Acute administration of ROCK inhibitors has resulted in modest pulmonary vasodilation in patients with PAH (85, 86), and chronic administration prevented pulmonary vascular remodeling in experimental pulmonary hypertension (87–91). The effects of long-term ROCK inhibition on the RV in PAH are unknown and, based on the available literature, both beneﬁcial (inhibition of apoptosis, reduction of inﬂammatory cell inﬂux) and detrimental effects (contractile depression and excessive reduction of hypertrophy) can be postulated (4). Statins may interfere with ROCK activation through inhibition of isoprenoid synthesis and subsequent Rho geranylgeranylation, which is the proposed mechanism by which statins reduce cardiac ROS production and hypertrophy after ATII infusion and pressure overload (92). Additional beneﬁcial effects of statins in heart failure consist of inhibition of ET-1 and renin–angiotensin signaling, stimulation of NO production, restoration of autonomic imbalance, and prevention of matrix metalloproteinase activation (93). Statins have been shown to be effective in reversing pulmonary vascular
remodeling and RV hypertrophy in the SU5416/hypoxia model (94), but the results from the clinical trial evaluating simvastatin in human PAH were disappointing (95). Control of Gene Expression by Histone Acetylation/Deacetylation
Histone-dependent packaging of genomic DNA is central mechanism for gene regulation in eukaryotes. When there is no transcription, DNA is wrapped around histone octameres in nucleosomes, which are the basic units of chromatin. The highly compact structure that is formed by interacting nucleosomes limits access of transcriptional enzymes to genomic DNA, thereby repressing gene expression (96). Acetylation of histones by histone acetylases relaxes the nucleosomal structures, thereby facilitating gene expression. The opposite effect is established by histone deacytelases (HDACs), which repress transcription. Inhibitors of HDACs have been shown to reverse pulmonary artery smooth muscle cell hypertrophy in experimental models of pulmonary hypertension (97). By repressing the transcription of genes encoding proteins involved in signaling that leads to cardiac hypertrophy (98, 99), HDAC inhibitors could be hypothesized to have positive direct effects on the RV. Surprisingly, RV adaptation to mechanical pressure overload in the pulmonary artery banding animal model is seriously hampered by the HDAC inhibitors, trichostatin A and valproic acid (66). The opposite effects of HDAC inhibitors in the two pressure-overloaded ventricles is a strong reminder of the fact that success of a drug in the treatment of left-sided heart failure does not guarantee beneﬁcial effects in the context of PAHassociated RV failure.
RV-Targeted Therapies: a New Concept Indeed, patients with PAH die of RV failure, and the prognostic role of the RV has recently been revisited. van de Veerdonk and colleagues (3) demonstrated that, even after decreasing the pulmonary vascular resistance with PAH-speciﬁc therapy, those patients that remain with low RV ejection fraction continue to have a poor prognosis. However, despite its prognostic importance, the cellular and molecular 1105
FOCUSED REVIEW mechanisms that explain RV failure are limited and frequently extrapolated from studies of chronic left heart failure. Nonetheless, there is increasing evidence to support the hypothesis that mechanisms of RV failure may not be identical to those of the LV. Some therapeutic options to treat left heart failure have been successfully applied to treat the RV in experimental PAH, but others have demonstrated contradictory results (Table 1). b-Adrenoreceptor Blockers
Similar to patients with left heart failure, PAH is characterized by increased activity of the sympathetic nervous system (which ﬁnding has prognostic signiﬁcance) (100) and down-regulation of the b-adrenergic receptor (AR) (101). Counteracting these mechanisms led to a ﬁrm central place of b-AR blocker treatment in patients with left heart failure (102). However, direct effects of b-AR blockade, such as systemic vasodilatation, reduction of myocardial contractility, and decreased heart rate, have prevented the use of this class of drugs in PAH. In portopulmonary hypertension, b-AR blockers have been associated with worsening hemodynamics and a decreased exercise capacity (103). There are, however, a number of reasons why the careful use of b-AR blockers in selected patients may be considered. The associated reduction of myocardial oxygen consumption is probably one of the explanations of the beneﬁt of b-AR blockers in heart failure. In addition, leakiness of the Ryanodine receptor is reversed by b-AR blockers, thereby restoring Ca21 handling and preventing calcineurin/nuclear factor of activated T cells up-regulation (104). b-AR blockers are effective in preventing arrhythmias, which is a problem associated with a markedly increased mortality in PAH (105). Interestingly, in a recent prospective study, So and collaborators (106) reported that the use of b-AR blockers in PAH is not uncommon, and, most importantly, this study reported no statistical differences in PAH-related hospitalization or all-cause mortality between patients with or without b-AR blocker treatment. However, a properly designed clinical trial to assess the safety of this class of drugs is warranted. Experimentally, carvedilol treatment improves exercise tolerance, induces RV capillarization, and improves RV function 1106
(107, 108). In another study in rats with MCT-induced pulmonary hypertension, bisoprolol treatment resulted in an improved RV–arterial coupling and improved survival (109). In comparison to the more selective b1-AR blockers, carvedilol has a unique mechanism by which it suppresses ventricular arrhythmias through inhibition of the spontaneous release of calcium from the sarcoplasmic reticulum (110). In addition, carvedilol has intrinsic antioxidant properties (111, 112) by which the drug is capable of preventing ROS-induced cardiomyocyte apoptosis (113). Some of the cardioprotective effects of carvedilol seem to be independent of blockade of the a- or b-AR, such as direct transactivation of the EGF-R via b arrestin stimulation (114) and up-regulation of the expression of the peroxisome proliferator–activated receptor g coactivator 1-a (PGC-1a), a master regulator of mitochondrial biology and cardiac metabolism (115). Another strategy to restore b-AR function without the negative chronotropic effects of b-AR blockade would be to prevent G protein– coupled receptor kinase-2–mediated uncoupling of b-AR using the small molecule, Gallein (116). Angiotensin-Converting Enzyme Inhibitors and AT1R Antagonists
Although the renin angiotensin system is clearly involved in pressure overload related cardiac remodeling, the role of angiotensin-converting enzyme (ACE) inhibitors and AT1R antagonists in PAH has not been thoroughly evaluated, and its use as a treatment for PAH-associated RV failure remains controversial. In a small case series study, 4 days of treatment with captopril reduced mean PAP and increased RV ejection fraction in three out of four patients (117). In another study, however, 12 weeks of captopril did not modify pulmonary hemodynamics or exercise capacity (118). Experimentally, both the ACE inhibitor, Ramipril, and the AT1R blocker, losartan, improved RV systolic function in rabbits subjected to pulmonary artery banding. In contrast, no direct effects of ACE inhibitors or AT1R blockers on RV function or hypertrophy were seen in experimental models of pulmonary hypertension (94, 119, 120). The improved RV function after pulmonary artery banding with ACE inhibition seem to be related to a decreased rate of apoptosis, but
not as a consequence of reduced hypertrophy (121). Metabolic Modulators
Abnormal mitochondrial metabolism has long been implicated in the development of chronic heart failure, and it has been proposed that a switch from aerobic to anaerobic metabolism could contribute to the development of RV failure (122, 123). Whereas it has been demonstrated that RV failure is characterized by increased expression of glycolysis-related genes (107) and increased glycolysis enzymatic rates (124), it is unclear whether this “metabolic remodeling” is an adaptive or a maladaptive response. We have demonstrated that, along with increased glycolysis, RV failure is characterized by a down-regulated expression of multiple genes required for fatty acids metabolism, supporting a switch in substrate utilization (125). The mechanisms responsible for the down-regulation of fatty acid oxidation in the failing RV are not well deﬁned, but reduced transcriptional activation of genes regulated by the coactivator PGC-1a and its corresponding nuclear receptor, peroxisome proliferator–activated receptor-a, appear to be involved (125). Multiple studies have shown that the rate of fatty acid oxidation is preserved or increased in physiological/adaptive LV hypertrophy, and that it decreases during the progression of heart failure (126). In a similar fashion, rats with adaptive RV hypertrophy after pulmonary artery banding have increased rates of fatty acid oxidation (127). However, whether or not decreased impaired fatty acid oxidation contributes to the development of RV failure has not been mechanistically evaluated. Metabolic modulators designed to block fatty acid oxidation, such as trimetazidine or ranolazine, have been used to prevent cardiac output reduction in rats with pulmonary artery banding; however, the effects of partial fatty acid oxidation inhibition is modest when treating established RV dysfunction (127). We have evaluated the effects of etomoxir, a potent fatty acid oxidation blocker in the SU5416/hypoxia PAH model, and report that etomoxir treatment neither worsens nor improves RV failure (Figure 1). Multiple clinical trials evaluating the role of fatty acid oxidation blockers in left heart failure have been designed; however, none of
AnnalsATS Volume 11 Number 7 | September 2014
2.0 TAPSE (mm)
1.5 1.0 P=0.013
at m tre
at m tre Pr e
Figure 1. (A) Inhibition of fatty acid oxidation with etomoxir treatment had no impact in mean pulmonary artery pressure (MPAP) in comparison to vehicletreated rats. (B) Paired analysis demonstrated that 2-week treatment with etomoxir was insufficient to prevent deterioration in right ventricular (RV) function, as assessed by tricuspid annulus plane systolic excursion (TAPSE). (C–E) Echocardiographic analysis demonstrates no difference in RV diastolic area between controls and vehicle- and etomoxir-treated rats. Asterisks indicate right ventricles; right ventricular end-diastolic diameters were (A) 1.37 mm, (B) 5.17 mm, and (C) 6.15 mm. Red dotted lines indicate left ventricles.
these metabolic modulators has become a standard treatment of heart failure (128). It has also been proposed that not only fatty acid oxidation, but also glucose oxidation, is impaired, and that it could be restored using a pyruvate dehydrogenase kinase inhibitor: dichloroacetate (DCA) (124). In MCT-induced pulmonary hypertension, DCA decreased the severity of pulmonary hypertension and regressed RV hypertrophy, an effect that was perhaps partially related to a reduction in afterload. The effects of DCA therapy were only moderate in pulmonary artery banding– induced RV hypertrophy (124). A clinical trial studying DCA in PAH-associated RV failure is currently underway (NCT01083524; www.clinicaltrials.gov). Antioxidants and Tetrahydrobiopterin
ROS have long been implicated in the pathobiology of chronic left heart dysfunction (129), but their role in RV Focused Review
failure remains to be investigated in depth. ROS can reduce myocyte contractility by affecting calcium handling through suppression of L-type Ca21 channels and sarco/endoplasmic reticulum Ca21ATPase: the Ca21-ATPase of the sarcoplasmic reticulum (130, 131). ROS can be generated from many sources (such as reduced nicotinamide adenine dinucleotide phosphate [NADPH] oxidases). In the heart, mitochondria are an important source of ROS, as they are generated as by-products of an incomplete reduction of oxygen in the electron transport chain. ROS are very unstable, electrophilic, and react with macromolecules, such as proteins and nucleic acids, generating adducts and altering function (132). Interruption of the ATII-Rho-NAD(P)H-ROS pathway with the xanthine oxidase inhibitor, allopurinol, improves myocardial contractility (133) and ameliorates chronic hypoxic PAH in rats (134). Hydralazine inhibits NADPH oxidase,
but it is unclear whether its antioxidant effects can be achieved at concentrations that are employed clinically (53). Another source of ROS in chronic pressure overload comes from uncoupled NO synthase (NOS) 3, and is associated with reduced availability of tetrahydrobiopterin (BH4), an NOS3reducing cofactor. Supplementing BH4 in a pressure overload mouse model of NOS3 uncoupling has been shown to be sufﬁcient to reduce ROS production and prevent maladaptive remodeling in experimental left heart failure (135). Probably the strongest evidence for the role of ROS in RV dysfunction comes from the study of hemeoxygenase-1 (HO-1) knockout mice. HO-1 plays a categorical role in the heart’s response to ROS by inducing the expression of genes that codify for antioxidant enzymes. However, Yet and collaborators (136) demonstrated that mice lacking HO-1 show severe RV dilatation and 1107
FOCUSED REVIEW infarction after hypoxia-induced pulmonary hypertension. On the other hand, we have shown that treatment with protrandim, up-regulates HO-1 expression and is associated with less RV dysfunction in experimental pulmonary hypertension (63). Importantly, ROS play a dual role in cells. Whereas ROS have a direct toxic effect, they also serve as signaling mediators to induce an antioxidant response (132). This dual role could potentially complicate the therapeutic potential of antioxidant treatment for RV failure.
Nonpharmacological RV-Targeted Therapies Exercise
It was previously believed that physical exercise had to be avoided by patients with PAH. After it was shown that exercise training corrected endothelial dysfunction and improved exercise capacity in chronic heart failure (137), a randomized controlled trial was designed to evaluate the effects of exercise rehabilitation in PAH (138). An exercise and respiratory training program of 4 months’ duration was well tolerated and improved scores of quality of life and exercise capacity (peak workload and oxygen uptake). The mean difference in the 6-minute walking distance between intervention and control groups (15 patients in both groups) was 111 m, which is a considerably larger improvement than observed in most PAH drug trials. Because systolic PAP at rest and exercise cardiac output did not change signiﬁcantly after training, the authors attributed the positive outcome to adaptations in gas exchange and respiratory and peripheral muscle function (138). However, hemodynamic data were obtained noninvasively, and the increase in peak oxygen uptake could have been due to an improvement in RV performance. Experimental data have suggested that exercise could have direct positive effects in the heart. For instance, exercise induces the expression of PGC-1a, which is also associated with increased vascular endothelial growth factor expression and reduced capillary rarefaction (139). However, whether PGC-1a–induced angiogenesis could explain an improvement in RV function after exercise training has yet to be determined. 1108
Cardiac dyssynchrony is a common problem in left heart failure, and even patients with mild-to-moderate LV systolic dysfunction beneﬁt from cardiacresynchronization therapy (140). Indeed, the Resynchronization–Deﬁbrillation for Ambulatory Heart Failure Trial showed that, among patients with New York Heart Association class II or III heart failure, a wide QRS complex, and LV systolic dysfunction, the addition of cardiac resynchronization therapy to an implantable cardioverter–deﬁbrillator reduced rates of death and hospitalization for heart failure (140). Recently, a post–follow-up analysis from the Multicenter Automatic Deﬁbrillator Implantation Trial with Cardiac Resynchronization Therapy demonstrated that, in patients with mild heart failure, LV dysfunction, and left bundle-branch block, early intervention with cardiac resynchronization therapy with a deﬁbrillator was associated with a signiﬁcant long-term survival beneﬁt. However resynchronization–deﬁbrillation did not confer any clinical beneﬁt in patients without left bundle-branch block (141). Ventricular dyssynchrony is also common in patients with PAH, and often easily recognized by echocardiogram (paradoxical septal movement); however, compared with the left heart failure, ventricular dyssynchrony in PAH is mostly caused by a difference in duration of RV contraction rather than a difference in the onset of contraction (142). There is signiﬁcantly less evidence to support the use of cardiac resynchronization therapy in patients with severe RV failure, but experimental data have demonstrated that RV pacing improves RV systolic function, improves adverse diastolic interaction, and resynchronized RV and LV peak pressures (143). A small study evaluating RV pacing in patients with chronic thromboembolic pulmonary hypertension demonstrated an improvement in diastolic relaxation, LV stroke volume, and RV contractility (144), but larger studies evaluating safety and efﬁcacy are warranted. Atrial Septostomy
It has been shown that some patients with PAH can beneﬁt from “decompressing” therapeutic strategies, such as atrial septostomy (AS) or Pott’s shunt. AS is a procedure that creates a right-to-left
shunt at the interatrial septum level with the use of a balloon catheter in a step-bystep fashion (145). This results in an increase in LV preload and systemic cardiac output at the expense of a drop in systemic percent SaO2. Theoretically, the drop in SaO2% is compensated by the increase in cardiac output, and thus systemic oxygen transport is maintained. AS may also decompress the RV by reducing its preload (146, 147). The results of this intervention are sometimes spectacular, with disappearance of syncope and ﬂuid retention within a matter of days; however, not all patients improve after septostomy, and the procedure is not risk free. In a recent review of almost 400 procedures performed worldwide (148), there was a 24-hour procedure-related mortality of about 7%, mainly resulting from refractory hypoxemia, and a 1-month mortality rate of 5% due to RV failure progression. It is fair to say, however, that, in most circumstances, this intervention has been performed in severely ill patients. There are no current guidelines for the optimal size of the shunt and, therefore, the appropriate size should be individualized. Massive right-to-left shunting as a result of an excessively large shunt may result in inadequate pulmonary blood ﬂow and severe, refractory hypoxemia and death— the aim is to achieve a fall in SaO2% below 10%. No studies have evaluated the effect of shunting on the RV at the molecular level. It is important to underscore the fact that balloon dilation AS should only be performed in centers experienced in both interventional cardiology and pulmonary hypertension. The creation of a post-tricuspid shunt (“Potts’ anastomosis”) instead of an interatrial shunt might be another (surgical or transcatheter) approach to manage refractory RV dysfunction in the setting of PAH, particularly in children (149). Mechanical RV Support and Transplantation
Mechanical support of the failing RV has generally been thought of as a palliative, temporary approach, although, as newer technologies develop, there continues to be an interest in the potential for longer-term support. Extracorporeal membrane oxygenation has been reported as a method to support the RV in patients with pulmonary hypertension and massive pulmonary embolism (150, 151). It can be implanted quickly, making it advantageous
AnnalsATS Volume 11 Number 7 | September 2014
FOCUSED REVIEW during emergent situations. Cannulae are implanted surgically, typically in a venoarterial arrangement, in which venous blood is withdrawn, pumped through an oxygenator, and then returned to the arterial system, bypassing the lungs. Risks include bleeding, thromboembolism, and vessel injury. Extracorporeal membrane oxygenation support is only temporary, and requires a plan for removal (i.e., there is a high likelihood of RV recovery, transplant within a short timeframe is likely and possible, or transition to a more permanent support [such as a RV assist device; to date, unlikely in PH] is an option). Mechanical circulatory assist devices, or ventricular assist devices (VADs), have been used in the setting of RV failure after cardiotomy, cardiac transplant, RV infarct,
or LV assist device (LVAD) implantation (152–155). They have not been used for the treatment of PAH-associated RV failure, largely owing to the concern of pulmonary hemorrhage due to input of high ﬂows into a diseased vasculature, which is a result of the pumps being designed for support of the LV. This has raised interest in the concept of partial-assist pumps that could provide enough ﬂow to assist circulation without the risk of pulmonary hemorrhage. Additional beneﬁts of a partial-assist pump would be a smaller device size that could reduce surgical times and complications. These potential beneﬁts must be weighed against the risk of thrombosis at lower ﬂows, which has been another limiting factor in adapting LV pumps to the RV. In addition to thromboembolism, other risks of
mechanical blood pumps to bear in mind are bleeding and infection. For RV support, blood is typically withdrawn from a cannula surgically placed in the RV and returned from the pump via a cannula in the pulmonary artery. Although originally developed for support of the LV, there are two devices approved by the U.S. Food and Drug Administration for support of the RV, the Thoratec PVAD and CentriMag (both manufactured by Thoratec, Pleasanton, CA). The Thoratec PVAD is a pneumatically driven pulsatile pump that can be used for long-term support. The CentriMag is a continuous-ﬂow pump used for short-term support (approved for up to 30 d) (156). The ﬁeld of cardiac mechanical support has progressed to preferentially use continuous-ﬂow (axial or
A. Insufficient hypertrophy/ growth arrest B. Capillary rarefaction/ decreased angiogenesis C. Metabolic remodelling/ Insufficient energy production D. Mitochondrial dysfunction E. RV-arterial uncoupling F. Increased ROS G. Extracellular matrix remodelling
Functional RV Hypertrophy
A. Sufficient hypertrophy B. Sufficient capillaries C. Sufficient energy D. Preserved mitochondrial function E. RV-A coupling
Maintenance of contractility at reduced energy consumption Reduction of fibrosis Improvement of capillary function Inhibition of inflammation and ROS stress Inhibition of apoptosis Maintenance of sufficient myocardial hypertrophy
Figure 2. Treatment goals for prevention of a deterioration of right ventricular (RV) function. After the initial hemodynamic changes in the lung circulation (reduced blood flow, increased resistance, and increased pulmonary artery pressure) the RV is capable of adaptation as long as there is sufficient hypertrophy, adequate capillary density, adequate substrate utilization and a controlled amount of reactive oxygen species (ROS). RV function decompensation may eventually occur, leading to severe RV dysfunction and failure. Treatment goals should be oriented toward maintenance of contractility with reduced energy consumption, prevention of metabolic remodeling, prevention of fibrosis, increased capillarization (induction of angiogenesis), control of ROS, adequate cell growth, and inhibition of cardiomyocyte apoptosis.
FOCUSED REVIEW centrifugal in design) devices as they are smaller and have improved durability. Two continuous-ﬂow devices have been developed that are placed percutaneously for temporary support: TandemHeart (CardiacAssist, Inc., Pittsburgh, PA) and Impella (Abiomed, Danvers, MA) (157– 159). The Impella has a unique design, with its small axial ﬂow pump being located on the end of the catheter, where it sits in the ventricle, and its adaptation for RV support, the Impella RP, recently received approval in Europe with a trial in the United States to start soon (160, 161). Lung Transplantation
Lung transplantation should be considered for severe PAH if the RV is not severely dysfunctional (typically deﬁned as the need for inotropic support), although such cases represent only 3% of all lung transplants (162). Combined heart–lung transplantation can occasionally be considering in cases of severe PAH with RV failure, although less than 100 cases are performed worldwide per year. Median survival after lung transplant is 5 years for PAH, which improves to 10 years for patients that survive the ﬁrst year after
transplant; similar results are seen for heart–lung transplant (163). The limited number of organs available requires better treatment strategies for RV failure in PAH.
Conclusions The ﬁrst decade of the 21st century ﬁnds the community of PAH trialists and researchers in a peculiar situation: the available drugs have some impact on patient survival, but do not alter the remodeled lung circulation. Conversely, effective treatments targeting the lung vessels could have detrimental effects on the failing RV. Thus, the development of PAH treatments that both reduce pulmonary vascular resistance and improve RV function is not straightforward. There are contrasting priorities within the different cell populations of heart and lungs. For example, we look for increased contractility in cardiomyocytes, but relaxation in pulmonary vascular smooth muscle cells. On the other hand, we look for apoptosis of the pulmonary endothelial cells in plexiform lesions, whereas we need to promote cardiomyocyte and cardiac
References 1 D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115: 343–349. 2 Sandoval J, Bauerle O, Palomar A, Gomez ´ A, Mart´ınez-Guerra ML, Beltran ´ M, Guerrero ML. Survival in primary pulmonary hypertension: validation of a prognostic equation. Circulation 1994; 89:1733–1744. 3 van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, Boonstra A, Marques KM, Westerhof N, VonkNoordegraaf A. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011;58:2511–2519. 4 Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009;135:794–804. 5 Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ, Nicolls MR. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J 2012;40:1555–1565. 6 Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation 2008;117:1717–1731. 7 Galie` N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al.; Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34: 1219–1263.
endothelial cell survival. However, it is very possible to deﬁne common goals. Mitigating the inﬂammatory response, preventing ROS/ reactive nitrogen species disequilibrium, and reversing extracellular matrix remodeling are likely to be beneﬁcial in both the heart and the pulmonary circulation. Aldosterone receptor blockers (and other inhibitors of the renin–angiotensin–aldosterone system), BH4, statins, and EGF-R blockers could fulﬁll the task. It may also be possible to speciﬁcally target the heart, without affecting pulmonary vasculature (Table 2). Speciﬁc support of RV function can perhaps be accomplished directly with carvedilol or metabolic modulators. Other important effects that ought to be considered for the treatment of RV failure are summarized in Figure 2. Finally, it is important to remember that PAH is a cardiopulmonary disease. Thus, as new treatments arise, trialists should not only focus on the lung circulation, but also consider every potential positive or negative effect that a drug may have on the RV. n Author disclosures are available with the text of this article at www.atsjournals.org.
8 Galie` N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013;62(25, Suppl):D60–D72. 9 Spruijt OA, Bogaard HJ, Vonk-Noordegraaf A. Assessment of right ventricular responses to therapy in pulmonary hypertension. Drug Discov Today (In press) 10 Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med 2005;258:199–215. 11 Gomez ´ A, Bialostozky D, Zajarias A, Santos E, Palomar A, Mart´ınez ML, Sandoval J. Right ventricular ischemia in patients with primary pulmonary hypertension. J Am Coll Cardiol 2001;38: 1137–1142. 12 Rich S, Kaufmann E, Levy PS. The effect of high doses of calciumchannel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76–81. 13 Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, Grunig ¨ E, Staehler G, Rosenkranz S, Halank M, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014;129:57–65. 14 Rich S, Seidlitz M, Dodin E, Osimani D, Judd D, Genthner D, McLaughlin V, Francis G. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998;114:787–792. 15 Tang WHW, Parameswaran AC, Maroo AP, Francis GS. Aldosterone receptor antagonists in the medical management of chronic heart failure. Mayo Clin Proc 2005;80:1623–1630. 16 Paramothayan NS, Lasserson TJ, Wells AU, Walters EH. Prostacyclin for pulmonary hypertension in adults. Cochrane Database Syst Rev 2005;(2):CD002994. 17 Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, Seeger W. Prostacyclin and its analogues in the
AnnalsATS Volume 11 Number 7 | September 2014
treatment of pulmonary hypertension. Pharmacol Ther 2004;102: 139–153. Achcar RO, Yung GL, Saffer H, Cool CD, Voelkel NF, Yi ES. Morphologic changes in explanted lungs after prostacyclin therapy for pulmonary hypertension. Eur J Med Res 2006;11:203–207. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, Grizzle WE, Aldred MA, Cool CD, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:261–272. Pogoriler JE, Rich S, Archer SL, Husain AN. Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension. Histopathology 2012;61:597–609. Yui Y, Nakajima H, Kawai C, Murakami T. Prostacyclin therapy in patients with congestive heart failure. Am J Cardiol 1982;50:320–324. Brittain EL, Pugh ME, Wheeler LA, Robbins IM, Loyd JE, Newman JH, Austin ED, Hemnes AR. Prostanoids but not oral therapies improve right ventricular function in pulmonary arterial hypertension. JACC Heart Fail 2013;1:300–307. Kerbaul F, Brimioulle S, Rondelet B, Dewachter C, Hubloue I, Naeije R. How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension. Am J Respir Crit Care Med 2007;175:846–850. van Albada ME, Berger RM, Niggebrugge M, van Veghel R, CrommeDijkhuis AH, Schoemaker RG. Prostacyclin therapy increases right ventricular capillarisation in a model for ﬂow-associated pulmonary hypertension. Eur J Pharmacol 2006;549:107–116. Syed AA, Gomez-Arroyo J, Sakagami M, Farkas L, Farkas D, AlHussaini AA, Kraskauskas D, Byron P, Voelkel NF. Inhaled iloprost improves right ventricular function in the Sugen5416/hypoxia model of severe pulmonary hypertension. Am J Respir Crit Care Med 2012;185:A3415. Hara A, Yuhki K, Fujino T, Yamada T, Takayama K, Kuriyama S, Takahata O, Karibe H, Okada Y, Xiao CY, et al. Augmented cardiac hypertrophy in response to pressure overload in mice lacking the prostaglandin I2 receptor. Circulation 2005;112:84–92. Francois H, Athirakul K, Howell D, Dash R, Mao L, Kim HS, Rockman HA, Fitzgerald GA, Koller BH, Coffman TM. Prostacyclin protects against elevated blood pressure and cardiac ﬁbrosis. Cell Metab 2005;2:201–207. Sueta CA, Gheorghiade M, Adams KF Jr, Bourge RC, Murali S, Uretsky BF, Pritzker MR, McGoon MD, Butman SM, Grossman SH, et al.; Epoprostenol Multicenter Research Group. Safety and efﬁcacy of epoprostenol in patients with severe congestive heart failure. Am J Cardiol 1995;75:34A–43A. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, HandbergThurmond E, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134:44–54. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, et al.; Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119–2125. Giannessi D, Del Ry S, Vitale RL. The role of endothelins and their receptors in heart failure. Pharmacol Res 2001;43:111–126. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504–509. Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M, Yamaguchi I, Goto K, Sugishita Y. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: marked increase in endothelin-1 production in the failing heart. Circulation 1996;93:1214–1222. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464–469. Sugden PH. An overview of endothelin signaling in the cardiac myocyte. J Mol Cell Cardiol 2003;35:871–886. Hilal-Dandan R, Ramirez MT, Villegas S, Gonzalez A, Endo-Mochizuki Y, Brown JH, Brunton LL. Endothelin ETA receptor regulates
signaling and ANF gene expression via multiple G protein–linked pathways. Am J Physiol 1997;272:H130–H137. Kawamura T, Ono K, Morimoto T, Akao M, Iwai-Kanai E, Wada H, Sowa N, Kita T, Hasegawa K. Endothelin-1–dependent nuclear factor of activated T lymphocyte signaling associates with transcriptional coactivator p300 in the activation of the B cell leukemia-2 promoter in cardiac myocytes. Circ Res 2004;94: 1492–1499. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002;8:35–40. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Luscher ¨ TF; EARTH investigators. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:347–354. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002;85:195–197. Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, Moriconi T, Rainisio M, Caspi A, Reizin L, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension—a multi-center randomized study. Cardiology 2008;109:273–280. Nagendran J, Sutendra G, Paterson I, Champion HC, Webster L, Chiu B, Haromy A, Rebeyka IM, Ross DB, Michelakis ED. Endothelin axis is upregulated in human and rat right ventricular hypertrophy. Circ Res 2013;112:347–354. McFarlane SI, Winer N, Sowers JR. Role of the natriuretic peptide system in cardiorenal protection. Arch Intern Med 2003;163: 2696–2704. Moreland RB, Goldstein I, Kim NN, Traish A. Sildenaﬁl citrate, a selective phosphodiesterase type 5 inhibitor. Trends Endocrinol Metab 1999;10:97–104. Galie` N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, et al.; Sildenaﬁl Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenaﬁl citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148–2157. Galie` N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, et al.; Pulmonary Arterial Hypertension and Response to Tadalaﬁl (PHIRST) Study Group. Tadalaﬁl therapy for pulmonary arterial hypertension. Circulation 2009;119:2894–2903. [Published erratum appears in Circulation 124:e279. Dosage error in article text.] Ghofrani HA, Galie` N, Grimminger F, Grunig ¨ E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, et al.; PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330–340. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenaﬁl preconditions adult cardiac myocytes against necrosis and apoptosis: essential role of nitric oxide signaling. J Biol Chem 2005; 280:12944–12955. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with sildenaﬁl attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005; 111:1601–1610. Zahabi A, Picard S, Fortin N, Reudelhuber TL, Deschepper CF. Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts. J Biol Chem 2003;278: 47694–47699. Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F, Molkentin JD, Drexler H, Wollert KC. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent
53 54 55
protein kinase type I in cardiac myocytes. Proc Natl Acad Sci USA 2002;99:11363–11368. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11:214–222. Hare JM, Stamler JS. NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 2005;115:509–517. Semigran MJ. Type 5 phosphodiesterase inhibition: the focus shifts to the heart. Circulation 2005;112:2589–2591. Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res 2007;100:1569–1578. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007;116:238–248. Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, Systrom DM, Bloch KD, Semigran MJ. Sildenaﬁl improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007;115:59–66. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenaﬁl improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebocontrolled study. Circ Heart Fail 2011;4:8–17. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011;124:164–174. Redﬁeld MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, et al.; RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013;309:1268–1277. Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V, Oudiz RJ, Boateng F, Scalise AV, Roessig L, et al.; Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial (LEPHT) Study Group. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 2013;128:502–511. Gan CT-J, Holverda S, Marcus JT, Paulus WJ, Marques KM, Bronzwaer JGF, Twisk JW, Boonstra A, Postmus PE, VonkNoordegraaf A. Right ventricular diastolic dysfunction and the acute effects of sildenaﬁl in pulmonary hypertension patients. Chest 2007; 132:11–17. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, Ockaili R, McCord JM, Voelkel NF. Chronic pulmonary artery pressure elevation is insufﬁcient to explain right heart failure. Circulation 2009;120:1951–1960. Guihaire J, Bogaard HJ, Flecher ´ E, Noly PE, Mercier O, Haddad F, Fadel E. Experimental models of right heart failure: a window for translational research in pulmonary hypertension. Semin Respir Crit Care Med 2013;34:689–699. Gomez-Arroyo J, Saleem SJ, Mizuno S, Syed AA, Bogaard HJ, Abbate A, Taraseviciene-Stewart L, Sung Y, Kraskauskas D, Farkas D, et al. A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. Am J Physiol Lung Cell Mol Physiol 2012;302:L977–L991. Bogaard HJ, Mizuno S, Hussaini AA, Toldo S, Abbate A, Kraskauskas D, Kasper M, Natarajan R, Voelkel NF. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am J Respir Crit Care Med 2011;183: 1402–1410. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811–2821.
68 Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412–1413. 69 Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, Smit EF, Vonk-Noordegraaf A. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J 2008;32:232–235. 70 Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006;145:152–153. 71 Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006; 61:736. 72 Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182:1171–1177. 73 Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galie´ N, Gomez-S ´ anchez ´ MA, Grimminger F, Grunig ¨ E, Hassoun PM, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013;127:1128–1138. 74 Edelberg JM, Lee SH, Kaur M, Tang L, Feirt NM, McCabe S, Bramwell O, Wong SC, Hong MK. Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart. Circulation 2002;105:608–613. 75 Hsieh PC, MacGillivray C, Gannon J, Cruz FU, Lee RT. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 2006;114:637–644. 76 Tang J, Kozaki K, Farr AG, Martin PJ, Lindahl P, Betsholtz C, Raines EW. The absence of platelet-derived growth factor-B in circulating cells promotes immune and inﬂammatory responses in atherosclerosis-prone ApoE2/2 mice. Am J Pathol 2005;167: 901–912. 77 Xaymardan M, Tang L, Zagreda L, Pallante B, Zheng J, Chazen JL, Chin A, Duignan I, Nahirney P, Raﬁi S, et al. Platelet-derived growth factor-AB promotes the generation of adult bone marrow–derived cardiac myocytes. Circ Res 2004;94:E39–E45. 78 Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114:763–776. 79 Shah AM, Campbell P, Rocha GQ, Peacock A, Barst RJ, Quinn D, Solomon SD; for the IMPRES Investigators. Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with signiﬁcant pulmonary arterial hypertension. Eur Heart J (In press) 80 Grossmann C, Krug AW, Freudinger R, Mildenberger S, Volker K, Gekle M. Aldosterone-induced epidermal growth factor receptor (EGFR) expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am J Physiol Endocrinol Metab 2007;292:E1790–E1800. 81 Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, et al. Aldosterone potentiates angiotensin II–induced signaling in vascular smooth muscle cells. Circulation 2004;109:2792–2800. 82 Merklinger SL, Jones PL, Martinez EC, Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 2005;112:423–431. 83 Nicolls MR, Mizuno S, Taraseviciene-Stewart L, Farkas L, Drake JI, Al Husseini A, Gomez-Arroyo JG, Voelkel NF, Bogaard HJ. New models of pulmonary hypertension based on VEGF receptor blockade–induced endothelial cell apoptosis. Pulm Circ 2012;2: 434–442. 84 Montani D, Seferian A, Savale L, Simonneau G, Humbert M. Druginduced pulmonary arterial hypertension: a recent outbreak. Eur Respir Rev 2013;22:244–250. 85 Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, Shimokawa H. Acute vasodilator effects of
AnnalsATS Volume 11 Number 7 | September 2014
a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005;91:391–392. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N, Nakano T. Beneﬁcial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006;70:174–178. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotalineinduced fatal pulmonary hypertension in rats. Circ Res 2004;94: 385–393. Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG, McMurtry IF. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rhokinase. Am J Physiol Lung Cell Mol Physiol 2004;287:L656–L664. Nagaoka T, Gebb SA, Karoor V, Homma N, Morris KG, McMurtry IF, Oka M. Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. J Appl Physiol (1985) 2006; 100:996–1002. Abe K, Tawara S, Oi K, Hizume T, Uwatoku T, Fukumoto Y, Kaibuchi K, Shimokawa H. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J Cardiovasc Pharmacol 2006;48:280–285. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, McMurtry IF. Rho kinase–mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007;100:923–929. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, Liao JK. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001;108:1429–1437. Lipinski MJ, Abbate A, Fuster V, Vetrovec GW. Drug insight: statins for nonischemic heart failure—evidence and potential mechanisms. Nat Clin Pract Cardiovasc Med 2007;4:196–205. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, Burns N, Kasper M, Voelkel NF. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006;291: L668–L676. Kawut SM, Bagiella E, Lederer DJ, Shimbo D, Horn EM, Roberts KE, Hill NS, Barr RG, Rosenzweig EB, Post W, et al.; ASA-STAT Study Group. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation 2011;123: 2985–2993. Fischle W, Wang Y, Allis CD. Histone and chromatin cross-talk. Curr Opin Cell Biol 2003;15:172–183. Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J, Wang D, Li M, McKinsey TA, Stenmark KR, et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 2012;126:455–467. Antos CL, McKinsey TA, Dreitz M, Hollingsworth LM, Zhang CL, Schreiber K, Rindt H, Gorczynski RJ, Olson EN. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 2003;278:28930–28937. Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T, Floss T, Goettlicher M, Noppinger PR, Wurst W, et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007;13:324–331. Ciarka A, Doan V, Velez-Roa S, Naeije R, van de Borne P. Prognostic signiﬁcance of sympathetic nervous system activation in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;181: 1269–1275. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV, et al. Betaadrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest 1992;89:803–815. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg ¨ A, van Veldhuisen DJ, Atar D, Hoes AW, et al.; ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment
of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10:933–989. [Published errata appear in Eur J Heart Fail 11:110; Eur J Heart Fail 12:416. Dosage error in article text.] Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006;130:120–126. Reiken S, Wehrens XH, Vest JA, Barbone A, Klotz S, Mancini D, Burkhoff D, Marks AR. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 2003;107:2459–2466. Tongers J, Schwerdtfeger B, Klein G, Kempf T, Schaefer A, Knapp JM, Niehaus M, Korte T, Hoeper MM. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 2007;153:127–132. So PP, Davies RA, Chandy G, Stewart D, Beanlands RS, Haddad H, Pugliese C, Mielniczuk LM. Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. Am J Cardiol 2012;109:1504–1509. Drake JI, Bogaard HJ, Mizuno S, Clifton B, Xie B, Gao Y, Dumur CI, Fawcett P, Voelkel NF, Natarajan R. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Biol 2011;45:1239–1247. Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ, Hoke NN, Kraskauskas D, Kasper M, Salloum FN, et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 2010;182:652–660. de Man FS, Handoko ML, van Ballegoij JJ, Schalij I, Bogaards SJ, Postmus PE, van der Velden J, Westerhof N, Paulus WJ, VonkNoordegraaf A. Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Heart Fail 2012;5:97–105. Zhou Q, Xiao J, Jiang D, Wang R, Vembaiyan K, Wang A, Smith CD, Xie C, Chen W, Zhang J, et al. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca21 release. Nat Med 2011;17:1003–1009. Ma XL, Yue TL, Lopez BL, Barone FC, Christopher TA, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia– reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther 1996;277:128–136. Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, Feuerstein G. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92–98. Wang R, Miura T, Harada N, Kametani R, Shibuya M, Fukagawa Y, Kawamura S, Ikeda Y, Hara M, Matsuzaki M. Pleiotropic effects of the beta-adrenoceptor blocker carvedilol on calcium regulation during oxidative stress-induced apoptosis in cardiomyocytes. J Pharmacol Exp Ther 2006;318:45–52. Kim IM, Tilley DG, Chen J, Salazar NC, Whalen EJ, Violin JD, Rockman HA. Beta-blockers alprenolol and carvedilol stimulate beta-arrestin–mediated EGFR transactivation. Proc Natl Acad Sci USA 2008;105:14555–14560. Drake JI, Gomez-Arroyo J, Dumur CI, Kraskauskas D, Natarajan R, Bogaard HJ, Fawcett P, Voelkel NF. Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional proﬁle in experimental pulmonary hypertension. Physiol Genomics 2013;45: 449–461. Piao L, Fang YH, Parikh KS, Ryan JJ, D’Souza KM, Theccanat T, Toth PT, Pogoriler J, Paul J, Blaxall BC, et al. GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension. Circulation 2012;126:2859–2869. Ikram H, Maslowski AH, Nicholls MG, Espiner EA, Hull FT. Haemodynamic and hormonal effects of captopril in primary pulmonary hypertension. Br Heart J 1982;48:541–545.
FOCUSED REVIEW 118 Leier CV, Bambach D, Nelson S, Hermiller JB, Huss P, Magorien RD, Unverferth DV. Captopril in primary pulmonary hypertension. Circulation 1983;67:155–161. 119 Rouleau JL, Kapuku G, Pelletier S, Gosselin H, Adam A, Gagnon C, Lambert C, Meloche S. Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and inﬂuence on angiotensin II type 1 receptor signaling pathway. Circulation 2001;104:939–944. 120 de Man FS, Tu L, Handoko ML, Rain S, Ruiter G, François C, Schalij I, Dorfmuller ¨ P, Simonneau G, Fadel E, et al. Dysregulated renin– angiotensin–aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:780–789. 121 Braun MU, Szalai P, Strasser RH, Borst MM. Right ventricular hypertrophy and apoptosis after pulmonary artery banding: regulation of PKC isozymes. Cardiovasc Res 2003;59:658–667. 122 Neubauer S. The failing heart—an engine out of fuel. N Engl J Med 2007;356:1140–1151. 123 Piao L, Marsboom G, Archer SL. Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure. J Mol Med (Berl) 2010; 88:1011–1020. 124 Piao L, Fang YH, Cadete VJ, Wietholt C, Urboniene D, Toth PT, Marsboom G, Zhang HJ, Haber I, Rehman J, et al. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med (Berl) 2010;88:47–60. 125 Gomez-Arroyo J, Mizuno S, Szczepanek K, Van Tassell B, Natarajan R, dos Remedios CG, Drake JI, Farkas L, Kraskauskas D, Wijesinghe DS, et al. Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. Circ Heart Fail 2013;6:136–144. 126 Abel ED, Doenst T. Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy. Cardiovasc Res 2011;90: 234–242. 127 Fang YH, Piao L, Hong Z, Toth PT, Marsboom G, Bache-Wiig P, Rehman J, Archer SL. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle’s cycle. J Mol Med (Berl) 2012;90:31–43. 128 Ashraﬁan H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation 2007;116:434–448. 129 Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005;115:500–508. 130 Nakaya H, Takeda Y, Tohse N, Kanno M. Mechanism of the membrane depolarization induced by oxidative stress in guinea-pig ventricular cells. J Mol Cell Cardiol 1992;24:523–534. 131 Kaplan P, Babusikova E, Lehotsky J, Dobrota D. Free radical-induced protein modiﬁcation and inhibition of Ca21-ATPase of cardiac sarcoplasmic reticulum. Mol Cell Biochem 2003;248:41–47. 132 Gems D, Partridge L. Stress-response hormesis and aging: “that which does not kill us makes us stronger”. Cell Metab 2008;7: 200–203. 133 Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, Marban ´ E, Hare JM. Allopurinol improves myocardial efﬁciency in patients with idiopathic dilated cardiomyopathy. Circulation 2001;104:2407–2411. 134 Hoshikawa Y, Ono S, Suzuki S, Tanita T, Chida M, Song C, Noda M, Tabata T, Voelkel NF, Fujimura S. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol (1985) 2001;90:1299–1306. 135 Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B, Lazzarino G, Paolocci N, Gabrielson KL, Wang Y, et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 2005;115:1221–1231. 136 Yet SF, Perrella MA, Layne MD, Hsieh CM, Maemura K, Kobzik L, Wiesel P, Christou H, Kourembanas S, Lee ME. Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase1 null mice. J Clin Invest 1999;103:R23–R29. 137 Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, Yu J, Adams V, Niebauer J, Schuler G. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in
patients with chronic heart failure. Circulation 1998;98:2709–2715. 138 Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger J, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006;114:1482–1489. 139 Chinsomboon J, Ruas J, Gupta RK, Thom R, Shoag J, Rowe GC, Sawada N, Raghuram S, Arany Z. The transcriptional coactivator PGC-1alpha mediates exercise-induced angiogenesis in skeletal muscle. Proc Natl Acad Sci USA 2009;106:21401–21406. 140 Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, et al.; Resynchronization-Deﬁbrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-tomoderate heart failure. N Engl J Med 2010;363:2385–2395. 141 Goldenberg I, Kutyifa V, Klein HU, Cannom DS, Brown MW, Dan A, Daubert JP, Estes NA III, Foster E, Greenberg H, et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med 2014;370:1694–1701. 142 Marcus JT, Gan CT, Zwanenburg JJ, Boonstra A, Allaart CP, Gotte ¨ MJ, Vonk-Noordegraaf A. Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underﬁlling. J Am Coll Cardiol 2008;51:750–757. 143 Handoko ML, Lamberts RR, Redout EM, de Man FS, Boer C, Simonides WS, Paulus WJ, Westerhof N, Allaart CP, VonkNoordegraaf A. Right ventricular pacing improves right heart function in experimental pulmonary arterial hypertension: a study in the isolated heart. Am J Physiol Heart Circ Physiol 2009;297: H1752–H1759. 144 Hardziyenka M, Surie S, de Groot JR, de Bruin-Bon HA, Knops RE, Remmelink M, Yong ZY, Baan J Jr, Bouma BJ, Bresser P, et al. Right ventricular pacing improves haemodynamics in right ventricular failure from pressure overload: an open observational proof-of-principle study in patients with chronic thromboembolic pulmonary hypertension. Europace 2011;13:1753–1759. 145 Sandoval J, Gaspar J, Pulido T, Bautista E, Mart´ınez-Guerra ML, Zeballos M, Palomar A, Gomez ´ A. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 1998;32:297–304. 146 Espinola-Zavaleta N, Vargas-Barron ´ J, Tazar JI, Casanova JM, Keirns C, Cardenas ´ AR, Gaspar J, Sandoval J. Echocardiographic evaluation of patients with primary pulmonary hypertension before and after atrial septostomy. Echocardiography 1999;16: 625–634. 147 Ciarka A, Vachiery ` JL, Houssiere ` A, Gujic M, Stoupel E, Velez-Roa S, Naeije R, van de Borne P. Atrial septostomy decreases sympathetic overactivity in pulmonary arterial hypertension. Chest 2007;131: 1831–1837. 148 Sandoval J, Torbicki A. Atrial septostomy. In: Voelkel NF, Schranz D, editors. Right ventricle in health and disease. London: Springer; 2014. 149 Esch JJ, Shah PB, Cockrill BA, Farber HW, Landzberg MJ, Mehra MR, Mullen MP, Opotowsky AR, Waxman AB, Lock JE, et al. Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience. J Heart Lung Transplant 2013;32:381–387. 150 Berman M, Tsui S, Vuylsteke A, Klein A, Jenkins DP. Life-threatening right ventricular failure in pulmonary hypertension: RVAD or ECMO? J Heart Lung Transplant 2008;27:1188–1189. 151 Berman M, Tsui S, Vuylsteke A, Snell A, Colah S, Latimer R, Hall R, Arrowsmith JE, Kneeshaw J, Klein AA, et al. Successful extracorporeal membrane oxygenation support after pulmonary thromboendarterectomy. Ann Thorac Surg 2008;86:1261–1267. 152 Furukawa K, Motomura T, Nose´ Y. Right ventricular failure after left ventricular assist device implantation: the need for an implantable right ventricular assist device. Artif Organs 2005;29: 369–377. 153 Kaul TK, Kahn DR. Postinfarct refractory right ventricle: right ventricular exclusion: a possible option to mechanical cardiac
AnnalsATS Volume 11 Number 7 | September 2014
support, in patients unsuitable for heart transplant. J Cardiovasc Surg (Torino) 2000;41:349–355. Klima U, Ringes-Lichtenberg S, Warnecke G, Lichtenberg A, Struber ¨ M, Haverich A. Severe right heart failure after heart transplantation: a single-center experience. Transpl Int 2005;18:326–332. Moazami N, Pasque MK, Moon MR, Herren RL, Bailey MS, Lawton JS, Damiano RJ Jr. Mechanical support for isolated right ventricular failure in patients after cardiotomy. J Heart Lung Transplant 2004; 23:1371–1375. Bhama JK, Kormos RL, Toyoda Y, Teuteberg JJ, McCurry KR, Siegenthaler MP. Clinical experience using the Levitronix CentriMag system for temporary right ventricular mechanical circulatory support. J Heart Lung Transplant 2009;28:971–976. Takagaki M, Wurzer C, Wade R, Lee R, Malaisrie SC, McCarthy PM, McGee EC Jr. Successful conversion of TandemHeart left ventricular assist device to right ventricular assist device after implantation of a HeartMate XVE. Ann Thorac Surg 2008;86: 1677–1679. Giesler GM, Gomez JS, Letsou G, Vooletich M, Smalling RW. Initial report of percutaneous right ventricular assist for right ventricular
shock secondary to right ventricular infarction. Catheter Cardiovasc Interv 2006;68:263–266. Prutkin JM, Strote JA, Stout KK. Percutaneous right ventricular assist device as support for cardiogenic shock due to right ventricular infarction. J Invasive Cardiol 2008;20:E215–E216. Cheung AW, White CW, Davis MK, Freed DH. Short-term mechanical circulatory support for recovery from acute right ventricular failure: clinical outcomes. J Heart Lung Transplant 2014;33:794–799. Goldstein JA, Kern MJ. Percutaneous mechanical support for the failing right heart. Cardiol Clin 2012;30:303–310. Yusen RD, Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, Kirk R, Lund LH, Rahmel AO, et al.; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: thirtieth adult lung and heart-lung transplant report— 2013; focus theme: age. J Heart Lung Transplant 2013;32:965–978. Schaffer JM, Singh SK, Joyce DL, Reitz BA, Robbins RC, Zamanian RT, Mallidi HR. Transplantation for idiopathic pulmonary arterial hypertension: improvement in the lung allocation score era. Circulation 2013;127:2503–2513.